Clinical Trial Update: BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This clinical trial update notes a Phase 1 study of BAL0891 by SillaJen in patients with advanced solid tumors, including triple-negative breast cancer, gastric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Gastric Cancer
• Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• BAL0891

Snippet

Sponsor: SillaJen, Inc. | Conditions: Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer | Phase 1 | Status: RECRUITING